Oxford University has launched a pioneering study which aims to significantly improve Covid and flu vaccine design for different age groups.
The Oxford Vaccine Group kickstarted the study last week, called LEGACY03, which is funded by the Medical Research Council, part of UK Research and Innovation.
It investigates how lymph nodes work and how they affect responses to vaccines in younger and older people.
The study is looking to enrol volunteers aged either between 18 to 45 years or 65 years and over at the time of screening and it will be based at the Centre for Clinical Vaccinology and Tropical Medicine at the Churchill Hospital in Oxford.
Participants will enrol for three months and the results will assist researchers in designing vaccines that offer greater protection to those most vulnerable to diseases like flu and Covid-19, particularly older people.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here